Brokerages Set Myriad Genetics (MYGN) PT at $31.17

Shares of Myriad Genetics (NASDAQ:MYGN) have been given an average recommendation of “Hold” by the fourteen analysts that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $30.91.

A number of research analysts recently issued reports on MYGN shares. Goldman Sachs started coverage on shares of Myriad Genetics in a research note on Monday, January 29th. They issued a “sell” rating and a $32.00 target price on the stock. Barclays raised their target price on shares of Myriad Genetics from $30.00 to $35.00 and gave the company an “equal weight” rating in a research note on Monday, January 22nd. Morgan Stanley upgraded shares of Myriad Genetics from an “underweight” rating to an “equal weight” rating and set a $28.00 target price on the stock in a research note on Wednesday, March 21st. ValuEngine lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Finally, BTIG Research set a $44.00 price target on shares of Myriad Genetics and gave the company a “buy” rating in a report on Wednesday, February 7th.

Myriad Genetics traded up $0.44, reaching $35.40, during midday trading on Thursday, Marketbeat.com reports. The stock had a trading volume of 573,121 shares, compared to its average volume of 678,820. Myriad Genetics has a 1-year low of $19.75 and a 1-year high of $41.57. The company has a current ratio of 3.52, a quick ratio of 3.16 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $2.47 billion, a PE ratio of 33.71, a PEG ratio of 3.81 and a beta of 0.51.

Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Tuesday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.04. Myriad Genetics had a net margin of 17.67% and a return on equity of 9.52%. The business had revenue of $193.50 million for the quarter, compared to analyst estimates of $188.22 million. During the same period last year, the business posted $0.27 EPS. Myriad Genetics’s revenue was down 1.7% compared to the same quarter last year. analysts anticipate that Myriad Genetics will post 1.2 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of MYGN. Louisiana State Employees Retirement System boosted its holdings in Myriad Genetics by 7.6% in the 4th quarter. Louisiana State Employees Retirement System now owns 29,800 shares of the company’s stock valued at $1,023,000 after purchasing an additional 2,100 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in shares of Myriad Genetics by 4.7% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 660,729 shares of the company’s stock worth $22,693,000 after acquiring an additional 29,797 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Myriad Genetics by 18.4% during the 4th quarter. Acadian Asset Management LLC now owns 2,205,297 shares of the company’s stock worth $75,743,000 after acquiring an additional 343,196 shares during the period. Unison Advisors LLC bought a new position in shares of Myriad Genetics during the 4th quarter worth about $456,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Myriad Genetics by 42.2% during the 4th quarter. SG Americas Securities LLC now owns 6,673 shares of the company’s stock worth $229,000 after acquiring an additional 1,979 shares during the period.

About Myriad Genetics

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply